Want to see JP:219A full AI Analyst Report?

Heartseed, Inc. (219A) Price & Analysis

5 Followers

219A Stock Chart & Stats

¥1804.00

-¥95.00(-2.73%)

At close: Jan 08 4:00 PM EST

¥1804.00

-¥95.00(-2.73%)

Day’s Range― - ―

52-Week Range¥1,365.00 - ¥3,210.00

Previous CloseN/A

Volume1.41M

Average Volume (3M)443.27K

Market Cap

¥69.13B

Enterprise Value¥31.86B

Total Cash (Recent Filing)¥7.34B

Total Debt (Recent Filing)¥890.00K

Price to Earnings (P/E)―

Beta0.71

Next Earnings

Nov 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)25.93

Shares Outstanding22,929,400

10 Day Avg. Volume566,730

30 Day Avg. Volume443,266

Financial Highlights & Ratios

PEG Ratio-2.00

Price to Book (P/B)5.17

Price to Sales (P/S)12.93

P/FCF Ratio37.21

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-94.5

Revenue Forecast (FY)¥451.00M

Bulls Say, Bears Say

Bulls Say

FY2025 Revenue And Profit TurnaroundThe FY2025 shift from steep losses to substantial revenue and operating profitability indicates a meaningful improvement in reported business performance. If maintained, stronger earnings can support reinvestment, reduce funding needs, and improve financial resilience over the next several quarters.

Positive Cash GenerationPositive operating and free cash flow in FY2025 shows that reported profitability translated into cash generation rather than remaining solely accounting-based. This strengthens internal funding capacity and gives the company more flexibility to support operations without relying as heavily on external capital.

Very Low Financial LeverageExtremely low leverage reduces interest and refinancing pressure while preserving balance-sheet flexibility. A strong equity position can help the company absorb operating volatility, continue investing, and fund future needs with less dependence on debt markets or constrained liquidity.

Bears Say

History Of Multi-Year LossesThe recent turnaround follows several years of steep losses, showing that profitability has not yet been demonstrated consistently across business cycles. This history raises execution risk because future earnings could weaken materially if the conditions supporting FY2025 performance do not persist.

Unproven Cash-Flow DurabilityThe contrast between earlier cash burn and FY2025 cash generation makes the latest improvement difficult to treat as fully established. If operating cash flow reverts toward prior levels, the company could again face greater funding dependence and reduced flexibility for investment or growth.

Inconsistent Gross-Profit ReportingInconsistent gross-profit reporting reduces confidence in comparing margins and assessing the underlying economics of the business over time. That makes it harder to determine how much of FY2025 profitability reflects durable operating improvement versus changes in reporting or revenue composition.

Heartseed, Inc. News

Heartseed Advances HS-005 Cardiac Cell Therapy With First Ischemic Heart Disease Patient Dosed

Heartseed, Inc. ( ($JP:219A) ) just unveiled an update. Heartseed Inc. has dosed the first patient with severe...

4d ago

219A

Heartseed Director Resigns After Appointment as Japan’s Digital Minister

Heartseed, Inc. ( ($JP:219A) ) has shared an update. Heartseed Inc. announced the resignation of independent board director...

1M ago

219A

Heartseed Secures ¥2 Billion Credit Line to Advance Heart Failure Cell Therapy

Heartseed, Inc. ( ($JP:219A) ) has provided an update. Heartseed Inc. has secured a 2 billion yen special...

3M ago

219A

Heartseed Books Subsidy-Driven Non-Operating Gain Without Changing Outlook

Heartseed, Inc. ( ($JP:219A) ) just unveiled an announcement. Heartseed Inc. reported non-operating income of 69,833 thousand yen...

3M ago

219A

Heartseed posts interim loss but keeps strong equity base as R&D weighs on 2026 outlook

Heartseed, Inc. ( ($JP:219A) ) has provided an update. Heartseed Inc. reported non-consolidated net sales of ¥467 million...

3M ago

219A

Heartseed doses first patient in EMERALD trial of HS-005 for dilated cardiomyopathy

Heartseed, Inc. ( ($JP:219A) ) just unveiled an announcement. Heartseed Inc. has begun dosing patients in its domestic...

5M ago

219A

Heartseed Advances HS-001 Heart Failure Therapy Toward Japan Approval After Positive Trial Readout

Heartseed, Inc. ( ($JP:219A) ) has issued an update. Heartseed Inc. reported results from its Phase I/II LAPiS...

5M ago

219A

Heartseed Narrows Quarterly Loss but Projects Deeper Full-Year Deficit

Heartseed, Inc. ( ($JP:219A) ) has provided an announcement. Heartseed Inc. reported non-consolidated net sales of ¥465 million...

6M ago

219A

Heartseed launches post-delivery RSU plan to align board pay with shareholder value

Heartseed, Inc. ( ($JP:219A) ) has shared an announcement. Heartseed Inc. has approved the grant of post-delivery restricted...

7M ago

219A

Heartseed revamps governance with new executive officer system and board changes

Heartseed, Inc. ( ($JP:219A) ) has provided an update. Heartseed Inc. announced it will introduce an executive officer...

8M ago

219A

219A FAQ

What was Heartseed, Inc.’s price range in the past 12 months?

Heartseed, Inc. lowest stock price was ¥1365.00 and its highest was ¥3210.00 in the past 12 months.

What is Heartseed, Inc.’s market cap?

Heartseed, Inc.’s market cap is ¥69.13B.

When is Heartseed, Inc.’s upcoming earnings report date?

Heartseed, Inc.’s upcoming earnings report date is Nov 13, 2026 which is in 13 days.

How were Heartseed, Inc.’s earnings last quarter?

Heartseed, Inc. released its earnings results on Aug 14, 2026. The company reported -¥21.7 earnings per share for the quarter.

Is Heartseed, Inc. overvalued?

According to Wall Street analysts Heartseed, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Heartseed, Inc. pay dividends?

Heartseed, Inc. does not currently pay dividends.

What is Heartseed, Inc.’s EPS estimate?

Heartseed, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Heartseed, Inc. have?

Heartseed, Inc. has 22,929,400 shares outstanding.

What happened to Heartseed, Inc.’s price movement after its last earnings report?

Heartseed, Inc. reported an EPS of -¥21.7 in its last earnings report. Following the earnings report the stock price went down -0.103%.

Which hedge fund is a major shareholder of Heartseed, Inc.?

Currently, no hedge funds are holding shares in JP:219A

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Heartseed, Inc.

Heartseed Inc. is a Japan-based company engaged in research and development of regenerative medicine products. The company has established cardiac regenerative medicine, a therapy in which microtissue derived from iPS cells is transplanted into the heart for patients with severe heart failure. Target diseases include dilated cardiomyopathy, old myocardial infarction, and dilated-phase hypertrophic cardiomyopathy.